Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (11): 1053-1059.DOI: 10.3969/j.issn.1673-8640.2024.11.005
Previous Articles Next Articles
LIU Junru, LI Meng, XU Yang, ZHENG Weiying
Received:
2023-10-13
Revised:
2024-06-28
Online:
2024-11-30
Published:
2024-11-29
CLC Number:
LIU Junru, LI Meng, XU Yang, ZHENG Weiying. Roles of urinary exosome miR-27a,miR-27b,miR-29c,miR-200c in diagnosis of early diabetic nephropathy[J]. Laboratory Medicine, 2024, 39(11): 1053-1059.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.11.005
基因名称 | 上游引物(5'~3') | 下游引物(5'~3') |
---|---|---|
miR-27a | CAACACCAGTCGATGGGCTGT | GTGCAGGGTCCGAGGT |
miR-27b | GGGGGTTCACAGTGGCTAAG | GTGCGTGTCGTGGAGTCG |
miR-29c | TTAATGCTAATCGTGATAAG | ACCTGAGAGTAGACCAGA |
miR-200c | GAGATGCGTGTGGGGTCAAG | CGGTGAACGGGCATGCCCGAC |
U6 | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT |
基因名称 | 上游引物(5'~3') | 下游引物(5'~3') |
---|---|---|
miR-27a | CAACACCAGTCGATGGGCTGT | GTGCAGGGTCCGAGGT |
miR-27b | GGGGGTTCACAGTGGCTAAG | GTGCGTGTCGTGGAGTCG |
miR-29c | TTAATGCTAATCGTGATAAG | ACCTGAGAGTAGACCAGA |
miR-200c | GAGATGCGTGTGGGGTCAAG | CGGTGAACGGGCATGCCCGAC |
U6 | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT |
组别 | 例数 | 年龄/岁 | 性别 | BMI/(kg·m-2) | 收缩压/kPa | 舒张压/kPa | |
---|---|---|---|---|---|---|---|
男/例 | 女/例 | ||||||
正常对照组 | 50 | 55.76±13.68 | 27 | 23 | 23.54±3.17 | 15.75±1.82 | 10.97±1.06 |
单纯T2DM组 | 135 | 57.52±12.57 | 79 | 56 | 25.01±3.62 | 16.67±2.34 | 11.20±1.53 |
早期DN组 | 82 | 58.54±9.43 | 50 | 32 | 24.35±4.06 | 16.52±2.72 | 11.39±1.65 |
临床期DN组 | 43 | 59.05±9.20 | 31 | 12 | 23.67±4.20 | 16.66±2.43 | 11.68±1.23 |
统计值 | 0.816 | 3.522 | 2.601 | 1.933 | 2.116 | ||
P值 | 0.486 | 0.318 | 0.052 | 0.124 | 0.098 |
组别 | 例数 | 年龄/岁 | 性别 | BMI/(kg·m-2) | 收缩压/kPa | 舒张压/kPa | |
---|---|---|---|---|---|---|---|
男/例 | 女/例 | ||||||
正常对照组 | 50 | 55.76±13.68 | 27 | 23 | 23.54±3.17 | 15.75±1.82 | 10.97±1.06 |
单纯T2DM组 | 135 | 57.52±12.57 | 79 | 56 | 25.01±3.62 | 16.67±2.34 | 11.20±1.53 |
早期DN组 | 82 | 58.54±9.43 | 50 | 32 | 24.35±4.06 | 16.52±2.72 | 11.39±1.65 |
临床期DN组 | 43 | 59.05±9.20 | 31 | 12 | 23.67±4.20 | 16.66±2.43 | 11.68±1.23 |
统计值 | 0.816 | 3.522 | 2.601 | 1.933 | 2.116 | ||
P值 | 0.486 | 0.318 | 0.052 | 0.124 | 0.098 |
组别 | 例数 | miR-27a | miR-27b | miR-29c | miR-200c |
---|---|---|---|---|---|
正常对照组 | 50 | 1.05±0.17 | 1.01±0.10 | 0.98±0.07 | 1.05±0.21 |
单纯T2DM组 | 135 | 1.81±0.49* | 2.29±0.92* | 0.87±0.08* | 1.52±0.54* |
早期DN组 | 82 | 3.24±1.25*# | 2.98±0.99*# | 0.61±0.05*# | 2.47±0.91*# |
临床期DN组 | 43 | 5.05±1.13*#∆ | 3.27±1.03*#∆ | 0.48±0.05*#∆ | 3.18±0.92*#∆ |
F值 | 235.624 | 70.351 | 672.304 | 108.127 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | miR-27a | miR-27b | miR-29c | miR-200c |
---|---|---|---|---|---|
正常对照组 | 50 | 1.05±0.17 | 1.01±0.10 | 0.98±0.07 | 1.05±0.21 |
单纯T2DM组 | 135 | 1.81±0.49* | 2.29±0.92* | 0.87±0.08* | 1.52±0.54* |
早期DN组 | 82 | 3.24±1.25*# | 2.98±0.99*# | 0.61±0.05*# | 2.47±0.91*# |
临床期DN组 | 43 | 5.05±1.13*#∆ | 3.27±1.03*#∆ | 0.48±0.05*#∆ | 3.18±0.92*#∆ |
F值 | 235.624 | 70.351 | 672.304 | 108.127 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | HbA1c/ (%) | UA/(μmol·L-1) | UUN/(mmol·L-1) | UCr/(μmol·L-1) | UAER/(μmol·L-1) | 校正TGF-β1/(μg·g-1Cr) |
---|---|---|---|---|---|---|---|
正常对照组 | 50 | 4.51±0.76 | 153.48±30.56 | 4.25±0.69 | 59.33±7.82 | 6.05±3.45 | 4.28±2.04 |
单纯T2DM组 | 135 | 8.48±2.33* | 213.67±57.85* | 6.34±1.03* | 78.94±11.73* | 9.80±4.05 | 11.19±5.16* |
早期DN组 | 82 | 8.67±2.26* | 384.92±117.60*# | 7.10±1.15*# | 94.36±15.48*# | 117.80±39.22*# | 21.74±9.83*# |
临床期DN组 | 43 | 9.10±2.74* | 526.31±179.38*#∆ | 8.68±1.47*#∆ | 134.25±27.98*#∆ | 495.28±149.50*#∆ | 33.56±17.41*#∆ |
F值 | 50.058 | 166.982 | 137.601 | 203.928 | 791.822 | 108.817 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | HbA1c/ (%) | UA/(μmol·L-1) | UUN/(mmol·L-1) | UCr/(μmol·L-1) | UAER/(μmol·L-1) | 校正TGF-β1/(μg·g-1Cr) |
---|---|---|---|---|---|---|---|
正常对照组 | 50 | 4.51±0.76 | 153.48±30.56 | 4.25±0.69 | 59.33±7.82 | 6.05±3.45 | 4.28±2.04 |
单纯T2DM组 | 135 | 8.48±2.33* | 213.67±57.85* | 6.34±1.03* | 78.94±11.73* | 9.80±4.05 | 11.19±5.16* |
早期DN组 | 82 | 8.67±2.26* | 384.92±117.60*# | 7.10±1.15*# | 94.36±15.48*# | 117.80±39.22*# | 21.74±9.83*# |
临床期DN组 | 43 | 9.10±2.74* | 526.31±179.38*#∆ | 8.68±1.47*#∆ | 134.25±27.98*#∆ | 495.28±149.50*#∆ | 33.56±17.41*#∆ |
F值 | 50.058 | 166.982 | 137.601 | 203.928 | 791.822 | 108.817 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
项目 | UUN | UCr | UA | 校正TGF-β1 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
r值 | P值 | r值 | P值 | r值 | P值 | r值 | P值 | ||||
miR-27a | 0.157 | 0.129 | 0.341 | <0.001 | 0.127 | 0.235 | 0.668 | <0.001 | |||
miR-27b | 0.118 | 0.287 | 0.198 | 0.001 | 0.078 | 0.654 | 0.429 | <0.001 | |||
miR-200c | 0.142 | 0.146 | 0.310 | <0.001 | 0.095 | 0.478 | 0.618 | <0.001 | |||
miR-29c | -0.135 | 0.185 | -0.269 | <0.001 | -0.109 | 0.369 | -0.502 | <0.001 |
项目 | UUN | UCr | UA | 校正TGF-β1 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
r值 | P值 | r值 | P值 | r值 | P值 | r值 | P值 | ||||
miR-27a | 0.157 | 0.129 | 0.341 | <0.001 | 0.127 | 0.235 | 0.668 | <0.001 | |||
miR-27b | 0.118 | 0.287 | 0.198 | 0.001 | 0.078 | 0.654 | 0.429 | <0.001 | |||
miR-200c | 0.142 | 0.146 | 0.310 | <0.001 | 0.095 | 0.478 | 0.618 | <0.001 | |||
miR-29c | -0.135 | 0.185 | -0.269 | <0.001 | -0.109 | 0.369 | -0.502 | <0.001 |
项目 | β值 | 标准误 | β'值 | t值 | P值 | 共线性结果 | |
---|---|---|---|---|---|---|---|
容差 | VIF值 | ||||||
HbAlc | 0.91 | 0.24 | 0.27 | 5.34 | <0.001 | 0.448 | 2.232 |
UCr | 6.43 | 2.12 | 0.41 | 8.96 | <0.001 | 0.574 | 1.743 |
miR-27a | 1.27 | 0.35 | 0.30 | 6.57 | <0.001 | 0.799 | 1.251 |
miR-27b | 0.83 | 0.29 | 0.09 | 2.12 | 0.001 | 0.759 | 1.317 |
miR-29c | 0.86 | 0.18 | 0.14 | 2.58 | 0.001 | 0.847 | 1.181 |
miR-200c | 1.13 | 0.20 | 0.26 | 5.10 | <0.001 | 0.801 | 1.274 |
项目 | β值 | 标准误 | β'值 | t值 | P值 | 共线性结果 | |
---|---|---|---|---|---|---|---|
容差 | VIF值 | ||||||
HbAlc | 0.91 | 0.24 | 0.27 | 5.34 | <0.001 | 0.448 | 2.232 |
UCr | 6.43 | 2.12 | 0.41 | 8.96 | <0.001 | 0.574 | 1.743 |
miR-27a | 1.27 | 0.35 | 0.30 | 6.57 | <0.001 | 0.799 | 1.251 |
miR-27b | 0.83 | 0.29 | 0.09 | 2.12 | 0.001 | 0.759 | 1.317 |
miR-29c | 0.86 | 0.18 | 0.14 | 2.58 | 0.001 | 0.847 | 1.181 |
miR-200c | 1.13 | 0.20 | 0.26 | 5.10 | <0.001 | 0.801 | 1.274 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
miR-27a | 0.823(0.717~0.902) | 2.85 | 55.00 | 97.06 | 0.520 6 |
miR-27b | 0.855(0.754~0.926) | 2.91 | 100.00 | 58.82 | 0.588 2 |
miR-29c | 0.799(0.689~0.883) | 0.57 | 90.00 | 61.76 | 0.517 6 |
miR-200c | 0.557(0.436~0.672) | 2.32 | 97.50 | 23.53 | 0.210 3 |
联合检测 | 0.923(0.848~0.977) | 0.81 | 80.00 | 97.05 | 0.770 6 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
miR-27a | 0.823(0.717~0.902) | 2.85 | 55.00 | 97.06 | 0.520 6 |
miR-27b | 0.855(0.754~0.926) | 2.91 | 100.00 | 58.82 | 0.588 2 |
miR-29c | 0.799(0.689~0.883) | 0.57 | 90.00 | 61.76 | 0.517 6 |
miR-200c | 0.557(0.436~0.672) | 2.32 | 97.50 | 23.53 | 0.210 3 |
联合检测 | 0.923(0.848~0.977) | 0.81 | 80.00 | 97.05 | 0.770 6 |
[1] |
BERMEJO S, GONZÁLEZ E, LÓPEZ-REVUELTA K, et al. The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes[J]. Clin Kidney J, 2023, 16(10):1656-1663.
DOI PMID |
[2] | International Diabetes Federation. IDF diabetes atlas 9th edition[EB/OL]. (2019-12-31)[2023-12-31]. https://diabetesatlas.org/atlas/ninth-edition/. |
[3] | ZHANG H, ZHU Y, HU Z, et al. Serum anti-phospholipase A2 receptor antibody in pathological diagnosis of type 2 diabetes mellitus patients with proteinuria[J]. Sci Rep, 2023, 13(1):16608. |
[4] | MISHRA D D, SAHOO B, MAURYA P K, et al. Therapeutic potential of urine exosomes derived from rats with diabetic kidney disease[J]. Front Endocrinol(Lausanne), 2023,14:1157194. |
[5] | 任亚丽, 卢学超, 解其华, 等. CTRP3、TGF-β1在糖尿病肾病中的表达及相关性研究[J]. 扬州大学学报(农业与生命科学版), 2022, 43(2):92-97. |
[6] | LUO C, LIU H, SHAO L, et al. The role of small extracellular vesicle non-coding RNAs in kidney diseases[J]. Front Genet, 2022,13:1013637. |
[7] | 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409. |
[8] | 黄秉文. 中美两种2型糖尿病肾病诊断标准中疾病进展及预后因素对比[J]. 医学信息, 2018, 31(22):68-72. |
[9] | 冒艳阳, 杨侠宇, 魏杰, 等. 尿TGF-β1、8-OHdG检测在早期糖尿病肾病中的应用价值[J]. 检验医学与临床, 2020, 17(24):3565-3567. |
[10] | 黄小抗, 朱启金, 吴永贵. 高糖刺激的巨噬细胞源外泌体对小鼠肾组织中TGF-β1/Smad3通路的影响作用[J]. 安徽医科大学学报, 2020, 55(1):1-6. |
[11] | 王唯一, 陈云霞, 赵雨, 等. miRNA-27与糖尿病肾病关系的研究进展[J]. 医学理论与实践, 2022, 35(22):3809-3811. |
[12] | LIN J, JIANG Z, LIU C, et al. Emerging roles of long non-coding RNAs in renal fibrosis[J]. Life, 2020, 10(8):131. |
[13] |
FAN Y, CHEN H, HUANG Z, et al. Emerging role of miRNAs in renal fibrosis[J]. RNA biology, 2020, 17(1):1-12.
DOI PMID |
[14] | 王一帆, 郭建波, 邵宝仪, 等. TGF-β1/SMAD在糖尿病肾病中的作用机制与研究进展[J]. 四川大学学报(医学版), 2023, 54(6):1065-1073. |
[15] | SHI M, TIAN P, LIU Z, et al. MicroRNA-27a targets Sfrp1 to induce renal fibrosis in diabetic nephropathy by activating Wnt/β-Catenin signalling[J]. Biosci Rep, 2020, 40(6):BSR20192794. |
[16] | PONTRELLI P, CONCERVA F, MENGHINI R, et al. Inhibition of lysine 63 ubiquitination prevents the progression of renal fibrosis in diabetic DBA/2J mice[J]. Int J Mol Sci, 2021, 22(10):5194. |
[17] | CHU J Y S, CHAU M K M, CHAN C C Y, et al. MiR-200c prevents TGF-β1-induced epithelial-to-mesenchymal transition and fibrogenesis in mesothelial cells by targeting ZEB2 and Notch1[J]. Mol Ther Nucleic Acids, 2019,17:78-91. |
[18] | 刘新磊, 宋卫敏, 高志强, 等. 抑制miR-200c表达对糖尿病肾病大鼠肾组织的保护作用及机制研究[J]. 中国临床解剖学杂志, 2019, 37(6):668-672. |
[19] |
SONODA H, LEE B R, PARK K H, et al. MiRNA profiling of urinary exosomes to assess the progression of acute kidney injury[J]. Sci Rep, 2019, 9(1):4692.
DOI PMID |
[20] | WANG S, YI P, WANG N, et al. LncRNA TUG1/miR-29c-3p/SIRT1 axis regulates endoplasmic reticulum stress-mediated renal epithelial cells injury in diabetic nephropathy model in vitro[J]. PLoS One, 2021, 16(6):e0252761. |
[21] | RAJABI S, SABERI S, NAJAFIPOUR H, et al. Interaction of estradiol and renin-angiotensin system with microRNAs-21 and-29 in renal fibrosis:focus on TGF-β/smad signaling pathway[J]. Mol Biol Rep, 2024, 51(1):137. |
[1] | WANG Xiaomei, LUO Chao, TIE Yang, HE Yong, YANG Xikui, LIU Yalin, SUN Yue, WANG Fugang, HE He. Application of random urine uric acid/creatinine in classification of hyperuricemia patients in Karamay [J]. Laboratory Medicine, 2024, 39(9): 859-864. |
[2] | GUO Chaonan, WANG Yanyan, ZHANG Bei, PANG Jingying, CUI Feifei, ZHAO Yongxin, SU Bing. Analysis of drug resistance and virulence of Klebsiella pneumoniae from different clinical samples [J]. Laboratory Medicine, 2024, 39(9): 880-887. |
[3] | WANG Limin, LIU Shanfeng, WANG Ping. Positive rate of urine cast after heart transplantation and its influencing factors [J]. Laboratory Medicine, 2024, 39(9): 900-904. |
[4] | LIU Ruishan, LONG Fengming, ZOU Chengli. Role of serum exosomal miR-93-5p determination in children with bronchial asthma [J]. Laboratory Medicine, 2024, 39(5): 449-453. |
[5] | LI Kejing, WANG Lin, YANG Ning. Relationship between NLR,TGF-β1 and Cav-1 levels and bleeding risk after mechanical thrombectomy for acute intracranial artery occlusion in elders [J]. Laboratory Medicine, 2024, 39(5): 480-484. |
[6] | WANG Rong, GAO Chunfang. Application progress of exosomal glycosylation in diagnosis and treatment of tumors [J]. Laboratory Medicine, 2024, 39(4): 404-409. |
[7] | CUI Xiaoyang, LIU Guodong, GUO Huijuan, LIAO Zhihong, LIU Yunhong, ZHANG Weifen, CHEN Zirao, WEI Xiaozhu. Roles of serum exosomal CEA,CA15-3 and CA125 in the differential diagnosis of non-small cell lung cancer and benign lung diseases [J]. Laboratory Medicine, 2024, 39(11): 1035-1041. |
[8] | LIU Jianxing, WANG Jinpeng, GENG Xinlong, WANG Shan. Role of urinary exosome miR-214 expression in diagnosis and prognosis assessment of clear cell renal cell carcinoma [J]. Laboratory Medicine, 2024, 39(10): 969-974. |
[9] | CHEN Wenju, ZHOU Yong, XU Jiajia, WANG Pan. Role of serum exosomal miR-23b-3p and miR-4429 in patients with hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 624-628. |
[10] | ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598. |
[11] | WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195. |
[12] | WANG Gangqiang, DIAO Yanjun, HE Juan, YANG Ruofan, YAN Hongbin, WANG Pei, LU Pei, LI Chenghua, XIAO Fengjing, ZHENG Shanluan, HAO Xiaoke, CHENG Xiang, LIU Jiayun. Establishment,verification and clinical application of automatic urine analysis system audit rule [J]. Laboratory Medicine, 2023, 38(10): 957-966. |
[13] | WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99. |
[14] | DUAN Yuping, XIE Li, CAI Leiming, WU Jingjing, HONG Mao, LI Qian. Correlation of serum exosomes,placental exosomes and exosomal miR-210 with preeclampsia [J]. Laboratory Medicine, 2022, 37(8): 715-719. |
[15] | PAN Fen, PAN Yuxuan, SHI Yingying, YU Fangyuan, ZHANG Hong. UroQuick rapid urine culture technique for urinary tract infection in children [J]. Laboratory Medicine, 2022, 37(7): 652-656. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||